文献速递浆细胞疾病造血干细胞移植与细胞治疗

接受T细胞重定向治疗的多发性骨髓瘤患者的非计划医疗互动

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性队列研究纳入46例对B细胞成熟抗原靶向双特异性抗体或CAR-T细胞治疗有反应的复发/难治性多发性骨髓瘤患者,评估治疗前125天内非计划医疗互动的频率和原因。结果显示89%患者发生非计划医疗互动,平均每人3.7次;双特异性抗体组远程联系医生办公室(增加1.8倍,P=0.038)和急诊就诊(增加三倍以上,P=0.012)显著多于CAR-T组,主要与轻度上呼吸道感染报告增多有关。

要点

  • 89%接受CAR-T或双特异性抗体治疗的患者在125天内发生非计划医疗互动,平均3.7次/人
  • 双特异性抗体组远程联系医生办公室风险为CAR-T组的1.8倍(P=0.038)
  • 双特异性抗体组急诊就诊风险为CAR-T组的3倍以上(P=0.012),与轻度上呼吸道感染增多有关

核心结论

  • 接受B细胞成熟抗原靶向CAR-T或双特异性抗体治疗且有反应的复发/难治性多发性骨髓瘤患者中,非计划医疗互动常见,需制定先发管理策略以减少不必要的医疗资源使用。

研究设计与样本

  • 回顾性队列研究,纳入46例对B细胞成熟抗原靶向双特异性抗体或CAR-T细胞治疗有反应的复发/难治性多发性骨髓瘤患者,分析治疗前125天内非计划医疗互动(包括电话联系医生办公室和在线患者门户消息等远程互动)的频率和原因。

主要发现

  • 89%的患者在治疗前125天内需要至少一次非计划医疗互动,平均每人3.7次。
  • 双特异性抗体组患者远程联系医生办公室的可能性是CAR-T组的1.8倍(P=0.038)。
  • 双特异性抗体组患者前往急诊就诊的可能性是CAR-T组的3倍以上(P=0.012),主要由于轻度上呼吸道感染报告增多。

临床怎么用

  • 作者认为,需针对接受CAR-T或双特异性抗体治疗的患者常见报告的症状制定先发管理策略,以显著减少这一脆弱人群不必要的医疗资源使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for patients with relapsed/refractory multiple myeloma (R/RMM) have dramatically improved after the development and now growing utilization of B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. However, health care utilization as a quality-of-life metric in these growing populations has not been thoroughly evaluated. We performed a retrospective cohort study evaluating the frequency and cause of unscheduled health care interactions (UHIs) among patients with R/RMM responding to B-cell maturation antigen-targeted BsAb and CAR T-cell therapies (N = 46). This included the analysis of remote UHIs including calls to physicians' offices and messages sent through an online patient portal. Our results showed that nearly all patients with R/RMM (89%) receiving these therapies required a UHI during the first 125 days of treatment, with a mean of 3.7 UHIs per patient. Patients with R/RMM responding to BsAbs were significantly more likely to remotely contact their physicians' offices (1.8-fold increase; P = .038) or visit an urgent care center (more than threefold increase; P = .012) than patients with R/RMM responding to CAR T-cell therapies. This was largely due to increased reports of mild upper respiratory tract infections in BsAb patients. Our results underscore the need to develop preemptive management strategies for commonly reported symptoms that patients with R/RMM experience while receiving CAR T-cell or BsAb therapies. This preemptive management may significantly reduce unnecessary health care utilization in this vulnerable patient population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Howard AJ, Concepcion I, Wang AX, et al. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies. Blood Adv. 2024. PMID: 38621239. doi:10.1182/bloodadvances.2024012871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。